TITAN PHARMACEUTICALS

Serial Number 85182788
606

Registration Progress

Application Filed
Nov 22, 2010
Under Examination
Dec 20, 2011
Approved for Publication
Oct 5, 2011
Published for Opposition
Oct 25, 2011
Registered

Basic Information

Serial Number
85182788
Filing Date
November 22, 2010
Published for Opposition
October 25, 2011
Abandonment Date
January 26, 2015
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 26, 2015
Classes
005

Rights Holder

Titan Pharmaceuticals, Inc.

03
Address
400 Oyster Point Boulevard, Suite 505
South San Francisco, CA 940801921

Ownership History

Titan Pharmaceuticals, Inc.

Original Applicant
03
South San Francisco, CA

Titan Pharmaceuticals, Inc.

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
Rosemary S. Tarlton

USPTO Deadlines

All Deadlines Cleared

All 4 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

40 events
Date Code Type Description
Jan 26, 2015 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Jan 26, 2015 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Jun 26, 2014 EXRA O NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Jun 25, 2014 EX5G S SOU EXTENSION 5 GRANTED
Jun 20, 2014 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 20, 2014 EXT5 S SOU EXTENSION 5 FILED
Jan 16, 2014 EXRA O NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Jan 15, 2014 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 15, 2014 EX4G S SOU EXTENSION 4 GRANTED
Dec 12, 2013 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 11, 2013 EEXT I SOU TEAS EXTENSION RECEIVED
Dec 11, 2013 EXT4 S SOU EXTENSION 4 FILED
Jul 11, 2013 EXRA O NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Jul 10, 2013 EX3G S SOU EXTENSION 3 GRANTED
Jul 9, 2013 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 11, 2013 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 11, 2013 EXT3 S SOU EXTENSION 3 FILED
Dec 18, 2012 EXRA O NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Dec 17, 2012 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 17, 2012 EX2G S SOU EXTENSION 2 GRANTED
Dec 10, 2012 EEXT I SOU TEAS EXTENSION RECEIVED
Dec 10, 2012 EXT2 S SOU EXTENSION 2 FILED
Jun 9, 2012 EXRA O NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Jun 7, 2012 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 7, 2012 EXT1 S SOU EXTENSION 1 FILED
Jun 7, 2012 EX1G S SOU EXTENSION 1 GRANTED
Dec 20, 2011 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT
Oct 25, 2011 PUBO A PUBLISHED FOR OPPOSITION
Oct 5, 2011 NPUB O NOTICE OF PUBLICATION
Sep 22, 2011 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 21, 2011 ALIE A ASSIGNED TO LIE
Sep 8, 2011 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 7, 2011 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 6, 2011 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 6, 2011 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2011 CNRT F NON-FINAL ACTION MAILED
Mar 2, 2011 DOCK D ASSIGNED TO EXAMINER
Mar 2, 2011 CNRT R NON-FINAL ACTION WRITTEN
Nov 29, 2010 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 25, 2010 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"